NICE (UK): Sparsentan can be used as option to treat primary immunoglobulin A nephropathy (IgAN) in adults with a: i) urine protein-to-creatinine ratio (UPCR) of 85 mg/mmol or… read more.
Novartis announced positive final results from APPLAUSE-IgAN, a Phase III study evaluating Fabhalta (iptacopan) in adults living with IgA nephropathy (IgAN). Fabhalta, an oral alternative complement pathway inhibitor,… read more.
Novartis announced that the FDA has granted accelerated approval for Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy… read more.
Calliditas Therapeutics has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Nefecon (budesonide), a novel oral formulation targeting down regulation of IgA1 for… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
